Simplify Logo

Full-Time

Senior Manager

QA Sterility Assurance & Contamination Control

Posted on 6/27/2024

ElevateBio

ElevateBio

201-500 employees

Develops and manufactures cell and gene therapies

Biotechnology
Healthcare

Senior

Waltham, MA, USA

This role is based in Waltham, Massachusetts, USA.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • BA/BS degree with 7+ years of experience in pharmaceutical, biotechnology, or biologics operation.
  • 5+ years of work experience in Microbiology Testing, Contamination Control, Aseptic Operations, and/or Sterility Assurance
  • Working knowledge of microbiological and sterility testing, aseptic process simulations, environmental monitoring, clean room management, cGMP regulations is required.
  • Strong communication and project management skills.
  • Ability to work well in a face paced environment.
Responsibilities
  • Lead management of the site contamination control strategy and program.
  • Facilitate microbiological/sterility assurance risk assessments.
  • Participate in root cause investigation for OOS and deviations for Sterility Assurance, Aseptic Processing, and Microbiological non-conformance events.
  • Author, review, and approve Quality records (deviations, CAPAs, change controls). and documentation (policies, standard operating procedures, work instructions).
  • Quality partner for aseptic process simulation design and execution for Cell and Gene Therapy programs.
  • Cross-functional on-the-floor coaching/training on aseptic operations, cleaning and microbial testing.
  • Interact with clients and regulatory agencies as an aseptic subject matter expert.

ElevateBio focuses on biotechnology, specifically in the cell and gene therapy market. They use proprietary technologies like gene editing and induced pluripotent stem cells (iPSC) to develop and manufacture therapies. Their integrated ecosystem allows them to support the entire process from discovery to commercialization, setting them apart from competitors. The goal is to advance scientific breakthroughs and deliver a wide range of effective therapies.

Company Stage

Series D

Total Funding

$1.2B

Headquarters

Waltham, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

24%

1 year growth

19%

2 year growth

32%
Simplify Jobs

Simplify's Take

What believers are saying

  • ElevateBio's recent $401 million Series D financing round, led by prominent investors, positions the company for accelerated growth and innovation.
  • The collaboration with the University of Pittsburgh to build the BioForge facility will significantly expand their manufacturing capabilities and technological infrastructure.
  • Their partnerships and commercialization efforts, including potential earnouts up to $2.35 billion with Novo Nordisk, offer substantial financial and developmental opportunities.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation and investment to maintain a leading position.
  • Dependence on strategic partnerships and collaborations may pose risks if these relationships encounter challenges or fail to deliver expected outcomes.

What makes ElevateBio unique

  • ElevateBio's integrated ecosystem of technologies and capabilities allows them to discover, develop, manufacture, and commercialize a broad spectrum of cell and gene therapies, setting them apart from competitors who may only focus on one aspect of the process.
  • Their strategic partnerships with industry leaders like Novo Nordisk and Kyverna Therapeutics enhance their technological and therapeutic development capabilities.
  • The company's proprietary technologies, such as gene editing and induced pluripotent stem cell (iPSC) platforms, provide a competitive edge in the biotechnology market.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE